Foghorn Therapeutics (FHTX) Net Income towards Common Stockholders (2019 - 2026)

Foghorn Therapeutics' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$80.6 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 250.88% year-over-year to -$80.6 million in Q1 2026; TTM through Mar 2026 was -$226.0 million, a 167.22% decrease from a year earlier, with the FY2025 full-year figure at -$265.3 million, down 206.26% from the prior year.
• Net Income towards Common Stockholders fell to -$80.6 million in Q1 2026 per FHTX's latest filing, from -$23.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$14.3 million in Q3 2023 and bottomed at -$80.6 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is -$25.8 million (2022), against an average of -$31.9 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 74.31% in 2022 and sank 250.88% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$28.9 million in 2022, then grew by 16.55% to -$24.1 million in 2023, then climbed by 19.09% to -$19.5 million in 2024, then dropped by 22.28% to -$23.8 million in 2025, then tumbled by 238.14% to -$80.6 million in 2026.
• Per Business Quant, the three latest FHTX Net Income towards Common Stockholders figures stand at -$80.6 million (Q1 2026), -$23.8 million (Q4 2025), and -$41.8 million (Q3 2025).